In summary, the present study describes a previously unrecognized activation of RhoA via ROR1/cortactin/ARHGEF1-dependent mechanism in response to Wnt5a, which prior studies found is present at high levels in the plasma of patients with CLL and is presumably present at even higher levels in lymphoid tissues. Here, RHOA is linked to B-cell chronic lymphocytic leukemia.